Tissue and circulating biomarkers in advanced melanoma patients receiving dabrafenib and trametinib.

Mandalà M, Tucci M, Sini MC, Baglivo S, Simi S, Costabile S, Gambale E, Quitadamo C, Leone P, Racanelli V, Doro MG, Frogheri L, Persico I, Viapiana N, Massi D, Palmieri G, TWIN group and Italian Melanoma Intergroup (IMI)

Journal of the European Academy of Dermatology and VenereologyIn the feed 4 Sep 2026, published online 4 Sep 2026, issue 2026 Sep 04, added to PubMed 4 Sep 2026

Topics: Skin cancer & tumors Melanoma & moles Cancer drugs

Read at publisher PubMed

Abstract

PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.

PMID 42695539 · DOI 10.1111/jdv.70697